Optimized antibodies that target CD19

US8524867B2 · kind B2 · utility

Assignee

• Xencor, Inc. · US

Inventors

• Matthew Bernett · Monrovia, US
• Seung Chu · Cypress, US
• John Desjarlais · Pasadena, US
• Sher Bahadur Karki · Pasadena, US
• Gregory Alan Lazar · Los Angeles, US
• Erik Weiking Pong · Temple City, US
• John O. Richards · Duarte, US
• Eugene Zhukovsky · West Hollywood, US

Key dates

• Filing date: Aug 14, 2007
• Grant date: Sep 3, 2013
• Expiry date: Aug 8, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.